This study is currently not recruiting participants.

Optimization of NULOJIX (Belatacept) Usage as a Means of Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

Not Recruiting
100 years or below
All
Phase N/A
1 Location

Brief description of study.

The purpose of this study is to find out if a new drug, belatacept, will minimize serious long term side effects seen with anti-rejection medications while still protecting the new pancreas and kidney from rejection.

Detailed description of study

The purpose of this study is to find out if a new drug, belatacept, will minimize serious long term side effects seen with anti-rejection medications while still protecting the new pancreas and kidney from rejection.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
  • Age: 100 years or below
  • Gender: All
Updated on 14 Nov 2014. Study ID: 1409104874

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team